Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
148 hedge funds and large institutions have $1.01B invested in Array Biopharma Inc in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 40 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
77% more call options, than puts
Call options by funds: $23.7M | Put options by funds: $13.4M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
11% more funds holding
Funds holding: 133 → 148 (+15)
4% less capital invested
Capital invested by funds: $1.05B → $1.01B (-$41.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.9M |
| 2 |
O
OrbiMed
New York
|
+$6.11M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.77M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$3.68M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$3.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$17M |
| 2 |
AC
Apex Capital
Orinda,
California
|
-$11.4M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$10.7M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.09M |
| 5 |
Millennium Management
New York
|
-$6.97M |
ARRY Hedge Fund Activity: Q2 2015 in Review
148 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2015, worth a combined $1.01B — down 3.9% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ARRY positions and 16 closed out — a net gain of 15 holders — while 53 added to existing stakes and 40 trimmed.
The largest buyer was Vanguard Group, adding an estimated $10.9M. The largest seller was Deerfield Management, cutting an estimated $17M.
- 148 institutional investors held Array Biopharma Inc (ARRY) as of Q2 2015, up from 133 in Q1 2015.
- Funds reported $1.01B of Array Biopharma Inc stock for Q2 2015, down 3.9% quarter-over-quarter.
- 31 funds opened new Array Biopharma Inc positions in Q2 2015 and 16 closed out, a net change of +15 holders.
- The largest Array Biopharma Inc buyer in Q2 2015 was Vanguard Group, an estimated $10.9M added.
- The largest Array Biopharma Inc seller in Q2 2015 was Deerfield Management, an estimated $17M sold.
Based on aggregated 13F filings for Q2 2015.